The systemic safety of bromfenac ophthalmic solution 0.09%

Journal of Ocular Pharmacology and Therapeutics

Volumn 23, Issue 6, 2007, Pages 601-612

  Stewart, Robert H ^a   Grillone, Lisa R ^b   Shiffman, Mitchell L ^c   Donnenfeld, Eric D ^d   Gow, James A ^e  

^a Houston Eye Associates   (United States)

^b PharmaQuest Associates LLC   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^d EAR AND THROAT HOSPITAL   (United States)

^e ISTA Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; PLACEBO;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CATARACT EXTRACTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG SELF ADMINISTRATION; EYE PAIN; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFLAMMATION; PRIVATE HOSPITAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT DURATION; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

AGED; ANTERIOR EYE SEGMENT; BENZOPHENONES; BROMOBENZENES; CATARACT EXTRACTION; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; LENS IMPLANTATION, INTRAOCULAR; LIVER FUNCTION TESTS; MALE; OPHTHALMIC SOLUTIONS; PAIN, POSTOPERATIVE; PHACOEMULSIFICATION; PLACEBOS; SELF ADMINISTRATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 36749092907     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0040     Document Type: Article

References (24)

1. Greaves, R.R., Agarwal, A., Patch, D., et al. Inadvertent diclofenac rechallenge from generic and nongeneric prescribing, leading to liver transplantation for fulminant liver failure. Eur. J. Gastroenterol. Hepatol. 13:71-73, 2001.
2. Aithal, G.P. Diclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicity. Exp. Opin. Drug Saf. 3:519-523, 2004.
3. O'Connor, N., Dargan, P.I., and Jones, A.L. Hepatocellular damage from non-steroidal anti-inflammatory drugs. QJM 96:787-791, 2003.
4. Jain, A.K., Hunley, C.C., Kuebel, J., et al. Analgesic efficacy of amfenac, aspirin, and placebo after extraction of impacted teeth. Pharmacotherapy 6:236-240, 1986.
5. Macario, A., and Lipman, A.G. Ketorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: A systematic review of efficacy, side effects, and regulatory issues. Pain Med. 2:336-351, 2001.
6. Walsh, D.A., Moran, H.W., Shamblee, D.A., et al. Anti-inflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3- benzoylphenylacetic acid and analogues. J. Med. Chem. 27:1379-1388, 1984.
7. Sancilio, L.F., Nolan, J.C., Wagner, L.E., et al. The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 37:513-519, 1987.
8. Food and Drug Administration. FDA Talk Paper: Wyeth-Ayerst Laboratories announces the withdrawal of Duract from the market. Available at: www.fda.gov/bbs/topics/ANSWERS/ANS00879. html 1998. Accessed on September 19, 2006.
9. Tinkleman, D.G., Rupp, G., Kaufman, H., et al. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv. Ophthalmol. 38(Suppl.):133-140, 1993.
10. Miyake-Kashima, M., Takano, Y., Tanaka, M., et al. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis. Jpn. J. Ophthalmol. 48:587-590, 2004.
11. Ohara, K., Ohkubo, A., Miyamoto, T., et al. Prevention of miosis during cataract surgery by topical bromfenac sodium. Jpn. J. Clin. Ophthalmol. 58:1325-1328, 2004.
12. Kawaguchi, T., Kida, T., Nemoto, S., et al. Effect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgery. Folia Ophthalmol. Jpn. 54:76-79, 2003.
13. Takamatsu, F., Shiroyama, N., Saito, Y., et al. Efficacy and adverse effects of bromfenac sodium following cataract surgery. Jpn. H. Clin. Ophthalmol. 57:1233-1237, 2003.
14. Ohara, K., Ohkubo, A., Miyamoto, T., et al. Effect of bromfenac sodium on postoperative inflammation. Jpn. J. Cataract Refract. Surg. 18:168-173, 2004.
15. Stewart, R.H., Walters, T.R., Cooke, D.L., et al. Integrated results from two phase III studies of topical Xibrom ™ 0.1%, an investigational NSAID for postcataract surgery inflammation. Poster presented at: AAO Annual Meeting, October 23-26, 2004, New Orleans, Lousiana.
16. Usui, M., and Masuda, K. Effect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitis. J. Rev. Clin. Ophthalmol. 91:39-44, 1997.
17. Seward, M.S., Cooke, D.L., Grillone, L.R., et al. Topical Xibrom™ 0.09%, significantly reduced ocular pain following cataract surgery. Poster presented at ARVO Annual Meeting, April 30-May 4, 2006, Ft. Lauderdale, Florida.
18. Nichols, J., and Synder, R.W. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr. Opin. Ophthal. 9:40-44, 1998.
19. Rho, D.S., Soll, S.M., and Markovitz, B.J. Treatment of acute pseudophakic cystoid macular edema: Bromfenac 0.09% versus diclofenac sodium 0.1% versus ketorolac tromethamine 0.5%. Poster presented at ARVO Annual Meeting, April 30-May 4, 2006, Ft. Lauderdale, Florida.
20. Ogawa, T., Sakaue, T., Terai, T., et al. Effects of bromfenac sodium, nonsteroidal anti-inflammatory drug, on acute ocular inflammation. Nippon Ganka Gakkai Zasshi (J. Jpn. Ophthalmol. Soc.) 99:406-411, 1995.
21. Kitao, N., Shimoji, H., and Fukuda, M. Postmarketing surveillance of bromfenac sodium (Bronuck®) ophthalmic solution. Jn. Eye 22:1299-1308, 2005.
22. Donnenfeld, E.D., Holland, E.J., Stewart, R.H., et al. Bromfenac ophthalmic solution 0.09% (Xibrom™) for postoperative ocular pain and inflammation. Ophthalmology 114:1653-1662, 2007.
23. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: World Health Organization, 1979.
24. Donnenfeld, E.D., and Donnenfeld, A. Global experience with Xibrom (bromfenac ophthalmic solution) 0.09%: The first twice-daily ophthalmic nonsteroidal anti-inflammatory drug. Int. Ophthalmol. Clin. 46(4): 21-40, 2006.